Satellos Bioscience Inc. (MSCLF)
OTCMKTS
· Delayed Price · Currency is USD
0.4600
-0.0200 (-4.17%)
May 16, 2025, 2:37 PM EDT
Satellos Bioscience Employees
As of December 31, 2024, Satellos Bioscience had 17 total employees, including 14 full-time and 3 part-time employees. The number of employees increased by 1 or 6.25% compared to the previous year.
Employees
17
Change (1Y)
1
Growth (1Y)
6.25%
Revenue / Employee
n/a
Profits / Employee
-$1,285,011
Market Cap
74.71M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 17 | 1 | 6.25% |
| Dec 31, 2023 | 16 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Endo Inc. | 3,116 |
| Tian'an Technology Group | 8 |
| Elite Pharmaceuticals | 64 |
| CytoDyn | 9 |
| Glass House Brands | 374 |
| Northwest Biotherapeutics | 25 |
| American Oncology Network | 1,914 |
| Silence Therapeutics | 116 |
Satellos Bioscience News
- 4 days ago - Satellos Reports First Quarter 2025 Results and Highlights Recent Company Progress - Business Wire
- 10 days ago - Satellos to Present at the CureDuchenne FUTURES National Conference - Business Wire
- 18 days ago - Satellos to Present at Bloom Burton & Co. Healthcare Investor Conference - Business Wire
- 6 weeks ago - Satellos to Participate in Two April Investor Conferences - Business Wire
- 7 weeks ago - Satellos Reports 2024 Financial Results and Highlights Company Progress - Business Wire
- 2 months ago - Satellos Presents Initial Data from the Phase 1 Trial of SAT-3247 at the 2025 Muscular Dystrophy Association Clinical & Scientific Conference - Business Wire
- 3 months ago - Satellos Announces Upcoming Presentation at the 2025 Muscular Dystrophy Association Clinical & Scientific Conference - Business Wire
- 3 months ago - Satellos Announces Completed Enrollment of all Four Multiple-Ascending Dose Cohorts for the Phase 1 Clinical Trial of SAT-3247 in Healthy Volunteers - Business Wire